Article Sidebar
Published:
Jan 26, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Protective effect of huperzine A against isoproterenol-induced myocardial damage in rats via regulation of PI3K/Akt signaling pathway
Abstract
Purpose: To investigate the cardioprotective effect of huperzine A (Hup A) against isoproterenol (ISO)- induced myocardial infarction (MI) in rats.
Methods: Forty healthy male rats were divided into 4 groups. Control rats received only saline. Rats in Hup A group were injected with Hup A (0.5 mg/kg) only; ISO-treated MI rats were injected with ISO, while ISO + Hup A rats were pre-treated with Hup A prior to ISO exposure and again treated with Hup A. Lipid levels, antioxidant status, cardiac markers, as well as the proteins associated with the PI3k/Akt signaling pathway were determined.
Results: Pre- and post-treatment with Hup A resulted in marked reductions in cardiac markers, heart weight, lipid peroxidation product (MDA), and lipid levels, along with improved antioxidant enzyme activities (p < 0.01). Rats treated with Hup A displayed normal cardiac fibrillar structure, relative to ISO- treated rats. Furthermore, the protein expression levels of Akt and PI3k (pAkt/Akt and pPI3k/PI3k ratios) were significantly upregulated (p < 0.01) in Hup A treated rats.
Conclusion: Pre- and post-treatment of rats with Hup A exerted potent cardioprotective effect against ISO-induced cardiac failure in rats. Thus, Hup A can potentially be developed as adjuvant therapy in clinical practice for alleviating MI-related problems.
